In today’s briefing:
- Paradigm Biopharmaceuticals (PAR AU): Comfortable Funding Position Through 2024
- Pre-IPO Weimeizi (Guangdong) – The Market Position Is Not Solid
Paradigm Biopharmaceuticals (PAR AU): Comfortable Funding Position Through 2024
- Paradigm Biopharmaceuticals (PAR AU) announced A$66 million capital raising, comprising A$45.7 million institutional placement and rights issue offer of A$20.3 million at A$1.30 per share.
- At the completion of the transaction, Paradigm will have a proforma cash position of $108.5 million, which funds the company into 2024.
- Paradigm is expected to announce data from one of its key trials related to knee OA pain in September, which will be a near-term catalyst for the company.
Pre-IPO Weimeizi (Guangdong) – The Market Position Is Not Solid
- WEIMEIZI develops the oral care market by means of large promotion and marketing so as to attract consumers, which helps Saky become one of the top brands in China.
- However, with the layout of other long-lasting reputable brands and the entry of new brands, how to maintain the market share in fierce competition has become an important issue.
- WEIMEIZI’s leading market position is not solid, unless it could create differentiated products and keep up with industry trends closely.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
